Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea · Delayed Price · Currency is KRW 4,560.00
-85.00 (-1.83%)
At close: Sep 11, 2026
Sinsin Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 123,051 | 113,778 | 106,388 | 102,586 | 91,926 | 74,008 |
Other Revenue | - | - | -0 | -0 | - | -0 |
| 123,051 | 113,778 | 106,388 | 102,586 | 91,926 | 74,008 | |
Revenue Growth | 14.86% | 6.95% | 3.71% | 11.60% | 24.21% | 10.25% |
Cost of Revenue | 75,002 | 70,769 | 70,278 | 69,274 | 61,706 | 52,318 |
Gross Profit | 48,049 | 43,009 | 36,110 | 33,312 | 30,220 | 21,689 |
Selling, General & Admin | 31,498 | 30,054 | 27,385 | 25,726 | 23,770 | 21,277 |
Research & Development | 720.28 | 898.01 | 474.5 | 488.03 | 89.9 | 709.07 |
Amortization of Goodwill & Intangibles | 17.15 | 17.15 | 15.79 | 14.09 | 9.43 | - |
Other Operating Expenses | 345.6 | 270.39 | 240.35 | 220.94 | 228.42 | 220.21 |
Operating Expenses | 33,511 | 32,219 | 29,220 | 27,308 | 24,794 | 23,032 |
Operating Income | 14,538 | 10,790 | 6,890 | 6,004 | 5,426 | -1,343 |
Interest Expense | -1,427 | -1,636 | -1,960 | -1,937 | -1,481 | -963.24 |
Interest & Investment Income | 52.84 | 31.04 | 37.83 | 40.34 | 8.3 | 2 |
Currency Exchange Gain (Loss) | 619.97 | -138.14 | 404.45 | 19.14 | 277.35 | 242.67 |
Other Non Operating Income (Expenses) | 444.74 | 586.64 | 84.44 | -131.88 | -222.32 | 331.37 |
EBT Excluding Unusual Items | 14,228 | 9,634 | 5,457 | 3,995 | 4,009 | -1,730 |
Gain (Loss) on Sale of Investments | 444.84 | 138.96 | -323.41 | - | - | - |
Gain (Loss) on Sale of Assets | 13.19 | 36.35 | 7 | -0 | 38.55 | 0.73 |
Asset Writedown | - | - | - | - | - | -18.16 |
Pretax Income | 14,686 | 9,809 | 5,141 | 3,995 | 4,047 | -1,747 |
Income Tax Expense | 1,282 | 526.37 | 329.15 | -651.57 | -308.12 | -297.73 |
Earnings From Continuing Operations | 13,405 | 9,282 | 4,811 | 4,646 | 4,355 | -1,449 |
Minority Interest in Earnings | 61.57 | 9.52 | 77.05 | 33.77 | 59.32 | -26.47 |
Net Income | 13,466 | 9,292 | 4,888 | 4,680 | 4,415 | -1,476 |
Net Income to Common | 13,466 | 9,292 | 4,888 | 4,680 | 4,415 | -1,476 |
Net Income Growth | 223.40% | 90.08% | 4.46% | 6.01% | - | - |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Change | -0.04% | -0.07% | 0.07% | - | - | - |
EPS (Basic) | 886.63 | 612.51 | 322.00 | 308.49 | 291.00 | -97.29 |
EPS (Diluted) | 886.63 | 612.51 | 322.00 | 308.49 | 291.00 | -97.29 |
EPS Growth | 223.53% | 90.22% | 4.38% | 6.01% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 11,754 | 6,971 | 4,439 | -1,081 | 4,553 | -2,659 |
Free Cash Flow Per Share | 773.90 | 459.53 | 292.38 | -71.27 | 300.15 | -175.28 |
Gross Margin | 39.05% | 37.80% | 33.94% | 32.47% | 32.87% | 29.31% |
Operating Margin | 11.82% | 9.48% | 6.48% | 5.85% | 5.90% | -1.81% |
Profit Margin | 10.94% | 8.17% | 4.59% | 4.56% | 4.80% | -1.99% |
Free Cash Flow Margin | 9.55% | 6.13% | 4.17% | -1.05% | 4.95% | -3.59% |
EBITDA | 18,607 | 14,942 | 11,150 | 9,941 | 9,184 | 2,329 |
EBITDA Margin | 15.12% | 13.13% | 10.48% | 9.69% | 9.99% | 3.15% |
D&A For EBITDA | 4,069 | 4,152 | 4,260 | 3,937 | 3,758 | 3,672 |
EBIT | 14,538 | 10,790 | 6,890 | 6,004 | 5,426 | -1,343 |
EBIT Margin | 11.82% | 9.48% | 6.48% | 5.85% | 5.90% | -1.81% |
Effective Tax Rate | 8.73% | 5.37% | 6.40% | - | - | - |
Advertising Expenses | - | 4,366 | 4,207 | 4,340 | 4,188 | 3,417 |